Shares of Nektar Therapeutics (NKTR) have been struggling lately and have lost 11.5% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could ...

Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...

Shares of Nektar Therapeutics (NASDAQ:NKTR) gained on Friday after Jefferies upgraded the stock noting an attractive risk-reward setup ahead of a mid-stage trial readout for the company’s lead ...

Nektar Therapeutics (NASDAQ:NKTR) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Nektar ...

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar ...

Nektar Therapeutics NKTR incurred a first-quarter 2025 adjusted loss of 22 cents per share, wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, the company had ...

Nektar Therapeutics has accused Eli Lilly of botching the analysis of data from phase 1b trials in eczema and psoriasis. Lilly, which has reportedly confirmed the errors, handed back rights to ...

Nektar announced that the ISLAND study of rezpeg in lupus failed to meet its primary endpoint and that Lilly would not be advancing the drug into Phase III studies. Rezpeg continues to show ...

Aug 7 (Reuters) - Nektar Therapeutics (NKTR.O), opens new tab on Monday sued Eli Lilly (LLY.N), opens new tab, accusing the U.S. drugmaker of undermining the prospects for a drug the companies ...

Nektar Therapeutics’ hopes of rebuilding its battered business around lupus lie in tatters. The key phase 2 clinical trial of rezpegaldesleukin missed its primary endpoint, prompting partner Eli ...